Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;43(6):311-319.
doi: 10.1097/DBP.0000000000001074. Epub 2022 Mar 21.

Predictors of Stimulant Medication Continuity in Children with Attention-Deficit/Hyperactivity Disorder

Kelly I Kamimura-Nishimura  1   2 , William B Brinkman  1   3 , Jeffery N Epstein  1   4 , Yin Zhang  1   5 , Mekibib Altaye  1   5 , John Simon  1   4 , Avani C Modi  1   4 , Tanya E Froehlich  1   2
Affiliations

Predictors of Stimulant Medication Continuity in Children with Attention-Deficit/Hyperactivity Disorder

Kelly I Kamimura-Nishimura et al. J Dev Behav Pediatr. .

Abstract

Objective: The objective of this study was to examine the simultaneous impact of patient-related and parent-related factors, medication-related factors, and health care system-related factors on attention-deficit/hyperactivity disorder (ADHD) medication continuity.

Method: Stimulant-naïve children (N = 144, M age = 8 yrs, 71% male) with ADHD completed a methylphenidate (MPH) trial and were followed for 1 year after trial completion and return to community care. Multivariable analysis investigated predictors of (1) having at least 1 filled ADHD prescription after return to community care versus none and (2) having more days covered with medicine after return to community care. Predictors included race; age; sex; income; baseline ADHD symptom severity; MPH trial experience; child and parent mental health conditions; and parent beliefs about ADHD, ADHD medications, and therapeutic alliance.

Results: One hundred twenty-one children (84%) had at least 1 filled ADHD medication prescription (mean = 178 d covered by medication) in the year after return to community care. Multivariable models found that a weaker perceived clinician-family working alliance predicted not filling any ADHD prescriptions. Among those who filled ≥1 prescription, factors linked to fewer days of ADHD medication coverage included child sociodemographic factors (non-White race, older age, being female, and lower income), lower parent beliefs that the child's ADHD affects their lives, and higher parent beliefs that medication is harmful, while child oppositional defiant disorder and parental ADHD predicted having more days of medication coverage.

Conclusion: Child demographic factors, parent beliefs, and medication-related factors are associated with continuation of ADHD medication. These findings may facilitate the development of effective strategies to improve ADHD medication continuity for children from diverse groups.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
Number of Days Covered with ADHD Medications after Leaving the Trial
See this image and copyright information in PMC

References

    1. Barkley RA, Fischer M, Smallish L, et al. Young adult outcome of hyperactive children: adaptive functioning in major life activities. J Am Acad Child Adolesc Psychiatry. 2006;45(2):192–202. - PubMed
    1. Wolraich ML, Chan E, Froehlich T, et al. ADHD Diagnosis and Treatment Guidelines: A Historical Perspective. Pediatrics. 2019;144(4). - PubMed
    1. Abikoff H, Hechtman L, Klein RG, et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry. 2004;43(7):802–811. - PubMed
    1. Barbaresi WJ, Katusic SK, Colligan RC, et al. Long-term school outcomes for children with attention-deficit/hyperactivity disorder: a population-based perspective. J Dev Behav Pediatr. 2007;28(4):265–273. - PubMed
    1. Lichtenstein P, Halldner L, Zetterqvist J, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med. 2012;367(21):2006–2014. - PMC - PubMed

Publication types

Substances